Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Ligand Pharmaceuticals (NASDAQ:LGND), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $133.71. Despite positive revenue growth, the company faces challenges with profitability and returns.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals has received mixed analyst ratings, with a majority being bullish. The average price target has increased, indicating positive sentiment. However, the company faces challenges with profitability and returns despite strong revenue growth.
The increase in the average price target and the majority of bullish ratings suggest a positive short-term outlook for LGND. However, the company's profitability challenges may temper this optimism. The strong revenue growth supports the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100